HC Wainwright & Co. Reiterates Buy on Ikena Oncology, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andres Maldonado has reiterated a Buy rating on Ikena Oncology (NASDAQ:IKNA) and maintained a $4 price target.
August 12, 2024 | 10:58 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andres Maldonado has reiterated a Buy rating on Ikena Oncology and maintained a $4 price target.
The reiteration of a Buy rating and the maintenance of a $4 price target by a reputable analyst can positively influence investor sentiment and potentially drive short-term price appreciation for Ikena Oncology.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100